Stockscreener 앱 받기
4.86
0.62%
0.03
시간 외 거래:
4.87
0.010
+0.21%
전일 마감가:
$4.83
열려 있는:
$4.75
하루 거래량:
677.72K
Relative Volume:
0.54
시가총액:
$316.19M
수익:
$297.18M
순이익/손실:
$-51.64M
주가수익비율:
-6.05
EPS:
-0.8033
순현금흐름:
$-50.72M
1주 성능:
-1.02%
1개월 성능:
+9.95%
6개월 성능:
-22.73%
1년 성능:
-63.92%
1일 변동 폭
$4.67
$4.91
1주일 범위
$4.67
$5.185
52주 변동 폭
$4.0913
$13.66
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.86 | 314.24M | 297.18M | -51.64M | -50.72M | -0.8033 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 다운그레이드 | Needham | Buy → Hold |
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com UK
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
New Highs: What is the earnings history of Evolus IncMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Evolus Earnings Call Signals Growth Amid Headwinds - The Globe and Mail
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Market Outlook: What analysts say about Evolus Inc stockTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Bank Watch: Can Evolus Inc navigate macro headwindsPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
(EOLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Can Evolus Inc. stock maintain growth trajectoryChart Signals & Community Consensus Trade Alerts - Naître et grandir
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - MarketBeat
Why Evolus Stock Soared Today - AOL.com
Evolus, Inc. (EOLS) matches Q4 earnings estimates - MSN
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX) - The Globe and Mail
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health - TipRanks
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives - simplywall.st
Evolus Q4 2025 slides: revenue growth continues despite forecast miss - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Evolus Up Over 26%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk - 富途牛牛
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Evolus, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
Evolus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Evolus Q4 2025 slides: revenue growth continues despite forecast miss By Investing.com - Investing.com Canada
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Evolus Q4 2025 Earnings Call Transcript - MarketBeat
Aug Sectors: What analysts say about Evolus Inc stockTrade Risk Assessment & AI Enhanced Trading Alerts - baoquankhu1.vn
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips - Investing.com Canada
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Bitget
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):